Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CKS1B | P61024 | 2/20 | 0.52 |
| ▸ | SKP1 | P63208 | 2/20 | 0.52 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.52 |
| ▸ | WNT3A | P56704 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | CCNK | O75909 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CCND3 | P30281 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18673194 | 0.90 | MAPT (0.59) | MAPTMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL25633952 | 0.89 | MAPT (0.58) | MAPTMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL25738496 | 0.89 | SMN1; SMN2 (0.61) | MAPTMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL14802410 | 0.88 | SMN1; SMN2 (0.60) | MAPTMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL29913781 | 0.88 | SMN1; SMN2 (0.60) | MAPTMEN1KMT2ASMN1; SMN2TSHR | |
| Lithium Ion SCHEMBL20163132 | 0.88 | MEN1 (0.57) | MAPTMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL24649711 | 0.86 | SMN1; SMN2 (0.56) | MAPTMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL30386022 | 0.86 | MAPT (0.56) | MAPTMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL22912831 | 0.86 | SMN1; SMN2 (0.65) | MAPTMEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL29020697 | 0.86 | MAPT (0.56) | MAPTMEN1KMT2ASMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028354-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | REGENT OF THE UNIV OF MICHIGAN (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260007681-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | UNIV MICHIGAN (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260000676-A1 | CHROMAN DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2025119380-A1 | ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | 江苏威凯尔医药科技股份有限公司 | 2025-06-12 | — | — | WO | disclosed |
| CN-120118067-A | Estrogen receptor modulators and uses thereof | 江苏威凯尔医药科技股份有限公司 | 2025-06-10 | — | — | CN | disclosed |
| EP-4554948-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Regents of the University of Michigan (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20250154141-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-05-15 | — | — | US | disclosed |
| US-20250129074-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2025-04-24 | — | — | US | disclosed |
| WO-2025067509-A1 | EGFR DEGRADANT, AND PREPARATION METHOD AND USE THEREFOR | 石药集团中奇制药技术（石家庄）有限公司 | 2025-04-03 | — | — | WO | disclosed |
| US-20250051324-A1 | PARP INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | KEYTHERA (SUZHOU) BIO-PHARMACEUTICALS CO., LIMITED (CN) | 2025-02-13 | — | — | US | disclosed |
| WO-2018098296-A1 | PIPERAZINE DERIVATIVES AS SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC (US) | 2018-05-31 | — | — | WO | disclosed |
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2018-05-24 | — | — | US | disclosed |
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2018-05-24 | — | — | US | disclosed |
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2018-05-24 | — | — | US | disclosed |
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| CN-102958917-B | Compositions and methods for modulating the wnt signaling pathway | IRM LLC (BM) | 2014-10-08 | — | — | CN | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
| CN-102958917-A | Compositions and methods for modulating the wnt signaling pathway | IRM LLC | 2013-03-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129074-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | AR, NR5A1, CYP17A1 | MAPT 3565/4885MEN1 770/4885KMT2A 3919/4885 |
| US-20250154141-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | BCL2, BCL2L2, BCL2L1 | MAPT 4377/4885MEN1 3782/4885KMT2A 1434/4885 |
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | MAPT 1345/4885MEN1 4086/4885KMT2A 103/4885 |
| US-20260028354-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESRRA, ESR2, ESRRB | MAPT 4305/4885MEN1 3661/4885KMT2A 2018/4885 |
| US-20260000676-A1 | CHROMAN DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESRRA, ESR2, ESRRB | MAPT 4644/4885MEN1 3970/4885KMT2A 1831/4885 |
| US-20250051324-A1 | PARP INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | PARP1, PARP2, PARP11 | MAPT 893/4885MEN1 1740/4885KMT2A 458/4885 |
| US-20260007681-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESRRA, ESR2, AR | MAPT 4310/4885MEN1 3918/4885KMT2A 1708/4885 |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | WNT3A, WNT1, WNT3 | MAPT 3765/4885MEN1 3006/4885KMT2A 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.